• About
    • Our Story
    • Management
    • Board of Directors
  • Science
  • Pipeline
    • BH-30643
    • BH-30236
    • Posters and Presentations
  • Clinical Trials
  • News
  • Careers
  • Contact
  • Menu Menu

About Us

We are building on our team’s exceptional track record of FDA-approved precision medicines to create the next leap forward in oncology and autoimmune diseases.

Learn More
scientist in lab
working in a lab

Science

Combining human intelligence, creative thinking and proven drug design expertise, we tackle some of the biggest challenges in oncology and autoimmune diseases.

Learn More

Pipeline

Medicines built from the ground up that aim to overcome the limitations of existing therapies.

Learn More

Clinical Trials

Explore our clinical trials and learn about how you can participate.

Learn More

Latest News

Learn More

BlossomHill Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12

January 5, 2026/in Press Releases/by David Anderson

January 5, 2026

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 David Anderson /wp-content/uploads/BlossomHill-Logo_FullColor.svg David Anderson2026-01-05 07:02:032026-01-05 07:02:03BlossomHill Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12

BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFRTM Inhibitor for NSCLC

December 9, 2025/in Press Releases/by eallison

December 10, 2025

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 eallison /wp-content/uploads/BlossomHill-Logo_FullColor.svg eallison2025-12-09 12:48:152025-12-09 15:30:48BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFRTM Inhibitor for NSCLC

BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS

November 3, 2025/in Press Releases/by David Anderson

November 3, 2025

Read more
/wp-content/uploads/BlossomHill-Logo_FullColor.svg 0 0 David Anderson /wp-content/uploads/BlossomHill-Logo_FullColor.svg David Anderson2025-11-03 08:15:482025-12-09 12:48:53BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS
© 2026 BlossomHill Therapeutics, Inc. | Terms of Service | Privacy Notice
Scroll to top Scroll to top Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Accept settingsHide notification only